Churg Strauss syndrome--successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment.

医学 泼尼松龙 内科学 不利影响 维持疗法 相伴的 甲氨蝶呤 外科 养生 肺炎 胃肠病学 化疗 肺
作者
Claudia Metzler,Bernhard Hellmich,Angela Gause,Wolfgang Ludwig Gross,Kirsten de Groot
出处
期刊:PubMed [National Institutes of Health]
卷期号:22 (6 Suppl 36): S52-S61 被引量:95
链接
标识
摘要

OBJECTIVE: To examine the safety and efficacy of methotrexate (MTX) plus low-dose prednisolone for induction of remission in non life- or organ-threatening courses and for remission maintenance in Churg-Strauss syndrome (CSS). METHODS: In an open-label study 11 patients were treated with MTXfor induction of remission at initial diagnosis and relapse. Twenty-five patients received MTX for maintenance of remission. Primary endpoints were the achievement of remission and the incidence of relapses, respectively. Doses of concomitant prednisolone (PRD) and side effects were secondary endpoints. RESULTS: Induction of remission was achieved in 8/11 patients with MTX/PRD. Median time to remission was 5 months (range 2-9). Remission was maintained in 12 of 23 with available long-term follow-up (median 48 months). Eleven patients experienced 8 major and 3 minor relapses with a median time from remission to first relapse of 9 months. With MTX, the median cumulative PRD dose during the induction phase was 6.2 g. In the maintenance phase PRD could be reduced by 53% in responders. Apart from one case of MTX-induced pneumonitis, adverse events were confined to mild/moderate episodes of infection and leucopenia. No opportunistic infections occurred, neither did steroid-specific adverse events. CONCLUSIONS: MTX is safe and effective for the induction of remission in non-life-threatening CSS. It allows a considerable reduction of PRD and thus avoidance of PRD-related adverse events. However, the ability of MTX to prevent relapses in CSS appears limited. The identification of an optimal maintenance regimen and prognostic factors for treatment response requires trials with larger patient numbers.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
科研通AI2S的应助被雪兔采纳,获得10
1秒前
稀饭完成签到,获得积分10
1秒前
共享精神的应助被梦锡采纳,获得10
2秒前
ygj发布了新的文献求助10
2秒前
努力加油干的小猫咪完成签到 ,获得积分10
2秒前
Jasper的应助被寒冷的断秋采纳,获得10
2秒前
小尾巴完成签到 ,获得积分10
2秒前
2秒前
2秒前
jyx发布了新的文献求助10
3秒前
wuhao完成签到 ,获得积分10
3秒前
马思维发布了新的文献求助10
4秒前
独木舟发布了新的文献求助10
4秒前
4秒前
feng完成签到,获得积分10
5秒前
Orange的应助被Muymaj采纳,获得10
5秒前
万能图书馆的应助被ifast采纳,获得10
5秒前
SciGPT的应助被贾文浩采纳,获得10
5秒前
1210xi完成签到,获得积分10
6秒前
忧虑的牛排完成签到,获得积分10
6秒前
呜呜完成签到,获得积分10
7秒前
甘甘甘甘的应助被先玉梅采纳,获得30
7秒前
形容完成签到,获得积分10
7秒前
feng发布了新的文献求助10
7秒前
DC-CIK军团完成签到 ,获得积分10
7秒前
科目三的应助被腼腆的妖妖采纳,获得10
8秒前
SciGPT的应助被科研通管家采纳,获得10
9秒前
Eliakim发布了新的文献求助10
9秒前
9秒前
molihuakai的应助被科研通管家采纳,获得10
9秒前
Hello的应助被科研通管家采纳,获得10
9秒前
9秒前
点点完成签到,获得积分10
9秒前
深情安青的应助被科研通管家采纳,获得10
9秒前
9秒前
Lucas的应助被科研通管家采纳,获得10
9秒前
zdd的应助被科研通管家采纳,获得10
9秒前
123564的应助被科研通管家采纳,获得10
9秒前
wanci的应助被科研通管家采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168144
求助须知:如何正确求助?哪些是违规求助? 9561199
关于积分的说明 21759542
捐赠科研通 7759434
什么是DOI,文献DOI怎么找? 3429948
关于科研通互助平台的介绍 2553742
邀请新用户注册赠送积分活动 2474463